Moderna’s Earnings Surprise and Analyst Downgrade
Lead: Moderna's stock takes a hit as HSBC analysts downgrade the vaccine maker despite strong quarterly results, raising concerns...
efficacy
KalVista’s Sebetralstat Study Shows Promising Results for Hereditary Angioedema
In a major breakthrough, KalVista Pharmaceuticals announced that its late-stage study of sebetralstat, a therapy for hereditary angioedema, has...
AN2 Therapeutics Shares Plummet 73% as Enrollment Paused for Epetraborole Trial
AN2 Therapeutics, a biopharmaceutical company, has seen its shares plummet by 73% after announcing a voluntary pause in Phase...
AN2 Therapeutics Pauses Phase 3 Enrollment for Epetraborole Trial
AN2 Therapeutics has voluntarily paused Phase 3 enrollment in its clinical trial for epetraborole in the treatment of MAC...
Moderna’s RSV Vaccine Faces Challenges Against Competitors
Moderna is preparing for a commercial battle with Pfizer and GSK as it plans to launch its respiratory syncytial...
BridgeBio Pharma’s NDA for Acoramidis Accepted by FDA
The U.S. FDA has accepted BridgeBio Pharma's New Drug Application for acoramidis, an investigational drug for Transthyretin Amyloid Cardiomyopathy....
Biogen Ends Development of Alzheimer’s Drug Aduhelm
Biogen, a biotechnology company, has announced that it will discontinue the development of its Alzheimer's disease drug, Aduhelm, which...
Promising Results for Vertex’s Non-Opioid Pain Pill
Vertex Pharmaceuticals' experimental non-opioid pain pill, VX-548, has shown promising results in studies as a potential alternative to opioids...
Positive Data from Silo Pharma’s Study on Alzheimer’s Treatment
In a groundbreaking study, Silo Pharma has announced that their Alzheimer's disease therapeutic, SPC-14, has shown positive efficacy in...
Nurix Therapeutics Receives FDA Fast-Track Designation for NX-5948
Nurix Therapeutics has received fast-track designation from the FDA for its treatment, NX-5948, for certain types of lymphocytic cancer....